Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis (AIH). More information about the ODD has been posted on www.fda.gov.AIH is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. The disease may occur in any ethnic group and at any age but is most often diagnosed in patients between age 40 and 50. It is estimated that the patient population in the